 |
 Video: What is a Stock Split?
|
|
|
| Aerovate Therapeutics is a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Co.'s initial focus is on developing AV-101, its dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. AV-101, delivered using a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug. According to our Aerovate Therapeutics stock split history records, Aerovate Therapeutics has had 0 splits. | |
|
Aerovate Therapeutics (AVTE) has 0 splits in our Aerovate Therapeutics stock split history database.
Looking at the Aerovate Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Aerovate Therapeutics shares, starting with a $10,000 purchase of AVTE, presented on a split-history-adjusted basis factoring in the complete Aerovate Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
07/01/2021 |
|
| End date: |
04/26/2024 |
|
| Start price/share: |
$19.41 |
|
| End price/share: |
$21.75 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
12.06% |
|
| Average Annual Total Return: |
4.12% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$11,206.76 |
|
| Years: |
2.82 |
|
|
|
|
|
